JPMorgan Chase & Co. Issues Pessimistic Forecast for Integra LifeSciences (NASDAQ:IART) Stock Price

Integra LifeSciences (NASDAQ:IART - Free Report) had its price objective lowered by JPMorgan Chase & Co. from $24.00 to $12.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has an underweight rating on the life sciences company's stock.

IART has been the subject of several other reports. Truist Financial reduced their price target on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a report on Friday, April 11th. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences presently has an average rating of "Hold" and a consensus target price of $18.63.

Integra LifeSciences Trading Down 5.0 %

Shares of IART traded down $0.64 during midday trading on Tuesday, reaching $12.25. The company had a trading volume of 1,542,604 shares, compared to its average volume of 1,037,372. The firm has a 50 day simple moving average of $18.93 and a 200-day simple moving average of $21.91. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The stock has a market cap of $951.97 million, a PE ratio of -136.10, a price-to-earnings-growth ratio of 0.73 and a beta of 1.27. Integra LifeSciences has a 1-year low of $11.60 and a 1-year high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. During the same quarter in the prior year, the business earned $0.55 earnings per share. Integra LifeSciences's revenue was up 3.7% on a year-over-year basis. Research analysts forecast that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds have recently bought and sold shares of the business. Arizona State Retirement System raised its holdings in Integra LifeSciences by 4.2% in the 1st quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company's stock worth $437,000 after acquiring an additional 795 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in shares of Integra LifeSciences by 7.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock worth $312,000 after purchasing an additional 913 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Integra LifeSciences by 4.6% during the first quarter. Envestnet Asset Management Inc. now owns 27,527 shares of the life sciences company's stock valued at $605,000 after purchasing an additional 1,204 shares during the period. Quadrant Capital Group LLC raised its stake in shares of Integra LifeSciences by 5,960.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 1,371 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Integra LifeSciences by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock worth $872,000 after purchasing an additional 1,437 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.